> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Valar Labs Wins Breakthrough Status for AI Bladder Cancer Test
- URL: https://www.fdaweb.com/valar-labs-wins-breakthrough-status-for-ai-bladder-cancer-test/
- Published: 2026-05-20T12:00:00.000Z
- Updated: 2026-09-14T13:39:35.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5161179

FDA has granted Valar Labs a breakthrough device designation for its Vesta Bladder Risk Stratify Dx test, an artificial intelligence-powered digital pathology tool designed to help predict outcomes for bladder cancer patients.

The company says the test is designed for use in patients with non-muscle-invasive bladder cancer, one of the most common forms of the disease. Currently, clinicians largely rely on traditional clinical and pathological measures such as tumor grade, stage and size to estimate recurrence and progression risk. Valar says its technology aims to improve risk stratification by applying AI models to standard hematoxylin and eosin-stained pathology slides routinely generated during clinical care.

The company says the test generates patient-specific prognostic assessments using proprietary AI foundation models that analyze pathology images for predictive signals not readily identifiable by human reviewers.

“For decades, urologists have managed bladder cancer with prognostic tools that leave too many patients in the gray zone,” said Trevor Royce, chief medical officer of Valar Labs. “Vesta Bladder Risk Stratify Dx gives clinicians the resolution they need to match treatment intensity to each patient’s true biological risk.”